Alemtuzumab, Fludarabine, Melphalan, and Thiotepa as a Reduced-Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Inborn Errors of Immunity.

Authors

• Thomas Pfeiffer
• Stephanie Hyde
• Feng Gao
• Shalini Shenoy
• Melissa Mavers
• Robert J. Hayashi
• Troy C. Quigg, Corewell Health West
• Michael J. Eckrich
• Lisa Madden
• Sima T. Bhatt

Document Type

Conference Proceeding

Publication Date

2-2025

Publication Title

Transplantation and Cellular Therapy

Abstract

Background: Allo-HCT is the only curative treatment for many inborn errors of immunity (IEI). The ideal conditioning regimen offers rapid engraftment, reduced organ toxicity, and low rates of GvHD. We report results of a phase 2 trial using a reduced intensity conditioning (RIC) regimen consisting of alemtuzumab, fludarabine, melphalan, and thiotepa for IEI patients.

Volume

31

Issue

2 Suppl

First Page

s176

Comments

Helen DeVos Children's Hospital

Tandem Meetings of ASTCT and CIBMTR, Feb 12-15, 2025, Honolulu, HI

Last Page

s177

Recommended Citation

Pfeiffer T, Hyde S, Gao F, Shenoy S, Mavers DM, Hayashi RJ, et al. [Quigg TC]. Alemtuzumab, fludarabine, melphalan, and thiotepa as a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplantation in inborn errors of immunity. Transplant Cell Ther. 2025;31(2 Suppl):s176-s7. doi: 10.1016/j.jtct.2025.01.272.

DOI

10.1016/j.jtct.2025.01.272

ISSN

2666-6367